ArticleJEADV clinical practice2026
Atopic Comorbidities Associated With Chronic Spontaneous Urticaria: A Case-Control Analysis of the All of Us Research Program.
Article in JEADV clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic spontaneous urticaria (CSU) is a mast cell-driven condition defined by recurrent wheals and/or angioedema lasting over 6 weeks without an identifiable trigger. Though CSU is known to co-occur with atopic diseases and share Th2-dominant immunologic pathways, prior studies have not adequately addressed these relationships in diverse populations. Objectives: To examine associations between CSU and atopic comorbidities in the All of Us (AoU) research program, a diverse, nationwide National Institutes of Health cohort focused on increasing enrollment from historically underrepresented groups. Methods: We conducted a matched, case-control study of AoU participants aged ≧ 18 years enrolled between May 6, 2018 and October 1, 2023. CSU cases were identified using SNOMED codes 51611005 and 42265009. Controls were matched 4:1 by age, sex, race, ethnicity, and smoking status. We compared rates of atopic dermatitis, allergic rhinitis, asthma, nasal polyps, food allergy, and drug allergy. Multivariable logistic regression adjusted for hypothyroidism, systemic lupus erythematosus, and rheumatoid arthritis given known associations with CSU. Results: We identified 1171 CSU cases and 4684 matched controls with no significant demographic differences. CSU patients had significantly higher rates of atopic dermatitis (12.6% vs. 1.7%, Conclusions: This study demonstrates a strong association between CSU and atopic disease in a racially and socioeconomically diverse cohort. Our findings highlight shared Th2-driven pathways underlying CSU and atopy and reinforce the potential utility of type 2 targeted therapies (e.g., dupilumab) in patients with CSU and comorbid atopic disease. Clinicians should screen CSU patients for atopic disease to help guide comprehensive, targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.